(Q54386562)

English

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. (English)

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

1 reference

based on heuristic

inferred from title

Razelle Kurzrock

12

object named as

Razelle Kurzrock

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

author name string

Daruka Mahadevan

1

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

Gregory Ryan Sutton

2

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

Rafael Arteta-Bulos

3

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

Chris J Bowden

4

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

Paul J E Miller

5

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

Rachel Elizabeth Swart

6

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

Mark S Walker

7

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

Paul Haluska

8

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

Pamela N Munster

9

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

John Marshall

10

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

Omid Hamid

11

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

publication date

4 January 2014

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

73

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

3

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

467-473

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

https://scigraph.springernature.com/pub.10.1007/s00280-013-2372-x

0 references

Insulin-like growth factors and neoplasia.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2372-X

21 January 2018

The insulin-like growth factor-I receptor as a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2372-X

21 January 2018

Disrupting insulin-like growth factor signaling as a potential cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2372-X

21 January 2018

Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2372-X

21 January 2018

Increased expression of insulin receptor substrate-1 in human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2372-X

21 January 2018

A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2372-X

21 January 2018

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2372-X

21 January 2018

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2372-X

21 January 2018

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2372-X

21 January 2018

A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2372-X

21 January 2018

Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2372-X

21 January 2018

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2372-X

21 January 2018

Identifiers

10.1007/S00280-013-2372-X

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/24390424

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54386562&oldid=1244291173"